Table 8.
Key achievements of not-for-profit Product Development Partnerships and their partners
| Disease | Medicine | |
|---|---|---|
| DNDi with Sanofi | Malaria | Artesunate-amodiaquine |
| DNDi with Farmanguinhos/Cipla | Malaria | Artesunate-mefloquine |
| DNDi with Laboratório Farmacêutico do Estado de Pernambuco (LAFEPE) | American trypanosomiasis (Chagas Disease) | Paediatric benznidazole |
| Institute for OneWorld Health (iOWH) | Leishmaniasis | Paromomycin |
| MMV with Novartis | Malaria | Artemether-lumefantrine dispersible tablets |
| MMV with Guilin | Malaria | Injectable artesunate |
| MMV with Sigma-Tau | Malaria | Dihydroartemisinin-piperaquine |
| MMV with Shin Poong | Malaria | Pyronaridine-artesunate |
| MMV with Guilin | Paediatric malaria | Sulfadoxine-pyrimethamine and amodiaquine |
| DNDi | African trypanosomiasis (sleeping sickness) | Nifurtimox and eflornithine combination therapy |
| DNDi | Visceral leishmaniasis (East Africa) | Sodium stibogluconate and paromomycin combination therapy |
| DNDi | Visceral leishmaniasis (Asia) | Liposomal amphotericin B, miltefosine, and paromomycin combination therapy |
Data from European Union Product Development Partnership Coalition. May 7, 2015. DNDi=Drugs for Neglected Diseases initiative. MMV=Medicines for Malaria Venture.